NOV 0.8 2005

Sheet

Under the Paperwood reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it contains a valid OMB control number to a collection of information unless it co

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Com	Complete if Known					
pplication Number	10/541,526					
lling Date	July 7, 2005					
rst Named Inventor	Stephen Robert Bloom					
roup Art Unit	1646					
xaminer Name						
ttorney Docket Number	AI 9250US					

				U.S. PATENT DOCU	MENTS	•	
xaminer Initials*	Cite No.1	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code ( (if known)				
ADK		5,026,685		Boublik, et al.	06-25-1991		
		5,574,010		McFadden	11-12-1996		
		5,604,203		Balasubramaniam	02-18-1997		
		5,696,093		Tseng, et al.	12-09-1997		
		6,046,167		Balasubramaniam	04-04-2000		
		6,191,102		DiMarchi, et al.	02-20-2001		
V		6,608,098		Nagase, et al.	08-19-2003		
ADK		6,620,910		Calas, et al.	09-16-2003		
•		<del>                                     </del>					
	ļ					· · · · · · · · · · · · · · · · · · ·	
	<del> </del>						
-							

		,		į	OREIGN PATENT DOCUMENT	S		
Examiner Initials*	Cite No.1					Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	L.
		Office.3	Number*	Kind Code <sup>5</sup> (if known)	7		• • • • • •	
ADK			0 619 332		Kuraray Co., Ltd.	10-12-1994		
			0 795 562		Kyowa Hakko Kogyo Co., Ltd.	09-17-1997		
			WO 93/19175		Thorens Bernard	09-30-1993		
			WO 99/43707		Novo Nordisk A/S	09-02-1999		
			WO 00/42026		Novonordisk AS and Agouron Pharma	07-20-2000		
ADK			WO 00/59887		Neurogen Corporation	10-12-2000		

Examiner's	Date Considered	
Signature		•

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

AI 9250US

Sheet

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Kute for form 1449A/PTO Complete if Known **Application Number** 10/541,526 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date July 7, 2005 First Named Inventor Stephen Robert Bloom **Group Art Unit Examiner Name** 

Attorney Docket Number

			·····		F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*		Cite No.1		Foreign Patent Docu	nent	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
		٠	Office.3	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			·	
AI	OK			WO 00/78333		Eli Lilly & Co.	12-28-2000		
				WO 01/04156		Zealand Pharmaceuticals	01-18-2001		
				WO 01/14368		Viropharma Incorporated	03-01-2001		
				WO 01/35988		Novo Nordisk A/S	05-25-2001		
				WO 01/66135		Novo Nordisk A/S	09-13-2001		
				WO 01/89554		Bionebraska, Inc. and & Sankyo Company, Ltd	11-29-2001		
				WO 02/03978		Metabasis Therapeutics, Inc	01-17-02		
				WO 02/66479		Banyu Pharmaceutical Co., Ltd	08-29-2002		
				WO 02/67918	·	Banyu Pharmaceutical Co., Ltd	09-06-2002		
	ĎK			WO 03/022304		IC Innovations	03-20-2003		
					<u> </u>			·	<u> </u>
					<u> </u>		·		ļ
ļ		ļ	<u> </u>			<u>                                     </u>	<del> </del>		<del> </del>
<u> </u>			<b>├</b>						<b></b>
			-				ļI		ļ
<u> </u>		ļ	-		4	·	<del>   </del>	· · · · · · · · · · · · · · · · · · ·	<del>   </del>
<b> </b>	<del></del>								<b>├</b> ──
<u> </u>		<b> </b> -	-		<del>- </del>		ļ		┼—
<u> </u>		<del> </del>	1		<del></del>				—
<b></b>	_	<u> </u>	-		+		· · · · · ·		┼
1		ı	ı	I	1				1.

OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner's Signature		Date Considered				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

45060805v1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

NOV

0 8 2009	O		s are required to respond to a collection of information w	nless il contains a valid OMB control number	PTO/SB/08A (10-96 Approved for use through 10/31/99, OMB 0551-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
BADOMB	Shetituto !	or form 1449			nplete if Known
	IN		TION DISCLOSURE NT BY APPLICANT	Application Number	10/541,526
· ·		(use as ma	iny sheets as necessary)		·
ŀ				Filing Date	July 7, 2005
				First Named Inventor	Stephen Robert Bloom
				Group Art Unit	1646
			•	Examiner Name	
Sheet	3	of	3	Attorney Docket Number	AI 9250US

Examiner's Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²					
		ADRIAN, et al., "Effect of peptide YY on gastric, pancreatic, and biliary function in humans," Gastroenterology, 89:494-499 (1985).						
		CUMMINGS, et al., "A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans", <i>Diabetes</i> , 50:1714- 1719 (2001).						
		DAKIN, et al., "Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats", Am J Physiol Endocrinol Metab., 283(6):E1173-7 (2002).						
		DAKIN, et al, "Oxyntomodulin inhibits food intake in the rat", Endocrinilogy, 142:4244-4250 (2001).						
		ENG, et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas", <i>J Biol Chem</i> , 267:7402-7405 (1992).						
		ENGLISH, "Food fails to suppress ghrelin levels in obese humans", J Clin Endocrinol Metab, 87:2984-87 (2002).						
		GHATEI, et al., "Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract", <i>J Clin Endocrinol Metab</i> , 57:488-495 (1983).						
		KREYMANN, "Glucagon-like peptide-1 7-36: a physiological incretin in man", Lancet, 2:1300-1304 (1987).						
		TATEMOTO, "Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion", <i>Proc. Natl. Acad. Sci.</i> , 79:2514-8 (1982).						
		UESAKA, et al., "Glucagon-like peptide isolated from the eel intestine: effects on atrial beating", <i>J Exp Biol.</i> , 204(Pt 17):3019-26 (2001).	!					
		WREN, et al., "Ghrelin enhances appetite and increases food intake in humans", J Clin Endocrinol Metab, 86:5992-5 (2001).						
ADK		WYNNE, et al., "Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial", <i>Diabetes</i> , 54(8):2390-5 (2005).	!					

Examiner's	/Andress D. Venen/	Date Considered 02/07/2007
Signature	/Andrew D. Kosar/	Date Considered 02/07/2007

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

## MAR. 20. 2006 10:56AM

PABST PATENT GROUP

## RECEIVED CENTRAL FAX CENTER

NO. 7336

MAR 2 0 2006 Please type a plus sign (4) inside this box --

PTO/SB/08A #18-85

Substitute for form 1449APTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)	Application Number	10/541,528	
	Filing Date	July 7, 2005	
	First Named Inventor	Stephen Robert Bloom	
	Group Art Unit	1646	
	Examiner Name		
1 of 1	Attorney Docket Number	AJ 9250US	

				MENTS	
Cite No. <sup>1</sup>	US Patent Document		S Patent Document Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passagas or Relevant Figures Appear
	(if k	(uwan)			
			DiMarchi, et al	06-24-2003	
	2004/0018975		DiMarchi, et al	01-29-2004	
	·				
	-		* * * * * * * * * * * * * * * * * * * *		
	No.1	No. <sup>1</sup> Number Kind (if I	Number Kind Code 2 (if known) 6,583,111	Cite No.1 US Patent Document Name of Patentee or Applicant of Cited Document  Number Kind Code 7 (if known)  6,583,111 DiMarchi, et al	Number   Kind Code 2     MM-DD-YYYY

					OREIGN PATENT DOCUMEN	TS			
Examiner Initials*	Clie No.1			Foreign Patent Doc.	ment	Name of Patentae or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te
		Office.	Number	(If known)		, , , , , , , , , , , , , , , , , , ,			
		-							
				+				ļ	
	-	<del>                                     </del>	<del>- :</del>				<del></del>	ļ	
		<del> </del>		1		<del></del>			
								<del> </del>	
					•				
<b></b>				<del></del>		<del>                                     </del>		_	

Examiner's Signature	/Andrew D. Kosar/	Data Considered 02/07/2007

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Tredement Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Petent, Washington, DC 20231.

AI 9250US

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not classon is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to application.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>2</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emparor must pracede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>9</sup> Applicant to place a check mark here if English language Translation is attached.